Suche
Mein Konto
Key CRISPR patent from Charpentier/Doudna is upheld by the China National Intellectual Property Administration
Charpentier/Doudna CRISPR patent is upheld by CNIPA: Learn how this decision affects the use of the technology worldwide. Discover RS Genomics' role in this global trend.
Key CRISPR patent from Charpentier/Doudna is upheld by the China National Intellectual Property Administration
RS Genomics Limited, founded to provide broad access to the fundamental CRISPR/Cas9 intellectual property, co-owned by Dr. Emmanuelle Charpentier announced today that its patent CN201380038920.6 has been upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidity action.
The patent was signed by Dr. Charpentier, along with the Regents of the University of California and the University of Vienna (collectively known as CVC), filed for “Methods and Compositions for RNA-Directed Target DNA Modification and RNA-Directed Transcription Regulation.” The decision to maintain patent law in China follows a recent decision by the Japanese Patent Office earlier this year to maintain JP6692856, also part of the CVC portfolio1.
Novelty and inventive step were disputed in the proceedings. In the decision, CNIPA rejected both challenges to patentability, including the claim that the priority application enabled the use of CRISPR/Cas9 in eukaryotic cells. CNIPA's decision to maintain the patent in full further proves its validity and value as part of the patent collection for the use of CRISPR/Cas9 technology.
Michael Arciero, vice president of intellectual property and commercial development at ERS Genomics, said:"CNIPA's decision is a testament to the strength of the foundational CVC CRISPR/Cas9 patent portfolio. Together with the recent decision in Japan, this highlights a global trend and highlights the importance of research organizations having the right intellectual property rights when working with this technology."
ERS Genomics provides licenses for the CRISPR/Cas9 technology to companies interested in using this technology in their commercial programs. With 89 patents in over 90 countries, ERS Genomics licenses these patents through its direct license from Emmanuelle Charpentier and now has nearly 150 licenses worldwide.
Sources: